HPGC(SH:600664) Shang Hai Zheng Quan Bao·2025-10-10 19:52Core Viewpoint - The announcement details the pledge situation of the controlling shareholder, Harbin Pharmaceutical Group Co., Ltd., indicating that the pledge risk is manageable and does not pose a threat of forced liquidation or transfer of shares [2][5][6]. Group 1: Shareholder Pledge Situation - Harbin Pharmaceutical Group holds 1,173,237,023 shares of the company, accounting for 46.58% of the total share capital, with 926,857,248 shares pledged, representing 79.00% of its holdings and 36.80% of the total share capital [2]. - The recent pledge situation change is a postponement of previously pledged shares and does not involve new pledges or releases [2][3]. - As of the announcement date, the cumulative pledged shares exceed 50% of the shares held by the controlling shareholder [4]. Group 2: Future Pledge and Financial Health - Within the next six months, 688,021,638 pledged shares will mature, which is 58.64% of the shares held by Harbin Pharmaceutical Group and 27.32% of the total share capital, with a corresponding financing balance of $80 million [5]. - There are no pledged shares maturing within the next year, excluding those maturing in the next six months [5]. - The financial condition of Harbin Pharmaceutical Group is stable, with sufficient capacity to repay, expected to come from self-funding and other sources [5][6]. Group 3: Impact on Company Operations - The pledge postponement will not materially affect the company's operations or governance, and there are no obligations for performance compensation from the controlling shareholder [6]. - The company will continue to monitor the pledge and release of shares by shareholders and comply with relevant disclosure obligations [6].